Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
Based on its recent analysis of the prostate cancer diagnosis market, Frost & Sullivan recognizes Hybridyne Technologies, Inc. with the 2010 North American Frost & Sullivan Award for Technology Innovation of the Year.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/frostsullivan/47727/
Legacy®, through an unrestricted educational grant from Genentech, launches two new resources devoted to helping smokers understand their risks for lung cancer and reducing their risks for mortality.
Lung cancer is the nation's number one cancer killer of both men and women, accounting for 28 percent of all cancer deaths. More Americans are killed by lung cancer than by breast cancer, prostate cancer, or any other cancer. Up to 90 percent of lung cancer cases result from smoking and no current treatment can cure lung cancer. Early detection is the key to better quality and longevity of life.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/legacy/47244/
EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today that new 10 year data from an international registry-based multi-center study shows 83 percent of patients had no biopsy evidence of disease after treatment with Ablatherm® HIFU, supporting the technology as a standard primary treatment for localized prostate cancer. Study results were presented at the American Urological Association (AUA) 2011 Annual Meeting, Washington, D.C.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/edap/49862/
Gen-Probe (NASDAQ: GPRO) announced today the US Food and Drug Administration (FDA) has approved its PROGENSA® PCA3 (Prostate Cancer gene 3) assay, the first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53530-gen-probe-progensa-pca3-prostate-cancer-psa
With the kick-off of pro football season and September marking National Prostate Cancer Awareness Month, the American Urological Association (AUA) Foundation and the National Football League (NFL) have teamed up for a third year to educate men about prostate health and encourage them to join the “Know Your Stats” campaign. With the support of an increasing number of NFL greats and prostate cancer survivors, the national campaign is focused on turning awareness into action by encouraging men to know their risks and get tested.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51874-aua-foundation-nfl-mike-haynes-know-your-stats-prostate-cancer-awareness
With September marking the kickoff of the pro-football season and National Prostate Cancer Awareness Month, the Urology Care Foundation and the National Football League (NFL) teamed up to release a new Public Service Announcement (PSA) focused on educating men about prostate cancer and encouraging them to join the Know Your Stats® campaign.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63352-nfl-and-urology-care-foundation-national-prostate-cancer-awareness-month
In partnership with Men’s Health Network (MHN), Prostate Health Education Network (PHEN), ZERO – the End of Prostate Cancer and Joe Torre, four-time world champion baseball Hall-of-Famer and prostate cancer survivor, Genomic Health, Inc. (Nasdaq: GHDX) today launched Your Prostate Your Decision to educate prostate cancer patients and their loved ones that every man is different and every cancer is unique, and a genomic test can clarify the aggressiveness of one’s disease prior to invasive treatment. This first-of-its-kind national effort aims to address concerning results of a large national survey that found low general awareness about prostate cancer aggressiveness and treatment options, underscoring the need for better understanding of active surveillance as a treatment plan.
“For a man with prostate cancer, a single decision can change his entire life,” said Mr. Torre, reflecting on his own experience with prostate cancer. “When I was diagnosed with prostate cancer, I faced a game-changing decision. While I chose surgery, a less aggressive approach called active surveillance might be the best choice.”
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322251-your-prostate-your-decision-joe-torre-talks-about-prostate-cancer-genomic-testing-treatment-options-psa/
Professor Puppet After Dark is brought to you by Adam & Eve. Go now to http://AdamAndEve.com and enter the Adam & Eve Coupon Code HANS to enjoy 50% OFF almost ANY item. Plus FREE Shipping , a FREE Special Gift, and FREE DVD’s.
Professor Hans and Penelope Lombard address an excellent viewer fan mail question from Lory this week. Will using a vibrator too often desensitize one from regular sex? There are two main results that you can get when using an electronic device or an artificial toy during solo play too often. One is that, essentially, you will get yourself numb and will crave for more powerful vibrations. Second, is that you will tend to train yourself to cum too quickly. We all know that women take a little longer to get off than men. Here’s another point though. It’s really good to have your prostate ejaculate maybe every couple of days but you just need to discipline yourself not to make it too often. Otherwise, you will lose your sexual appetite.
Steve Scott became one of the greatest mile runners in American history by taking a strategic approach to his craft. Now 58, Scott is seeking a competitive advantage of a different sort since recently being diagnosed with prostate cancer. Scott publicly revealed his current cancer battle today at the Cougar Challenge, a cross country meet at California State University San Marcos, where he is head coach of the track and field and cross country programs.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7350051-scripps-health-steve-scott-reveals-proton-treatments-for-prostate-cancer
Experience prostate-centered orgasms with this flexible silicone massager! Its contoured head is shaped to slide in comfortably when lubed and stays right where you need it. A perfectly placed textured nub also stimulates perineum for added sensations. Just press the button and powerful vibrations for deep orgasms!
Finally, the perfectly sized prostate vibe in the perfectly safe material. Its round head always hits the spot and the flexible body that is ideally shaped to surround the perineum with gentle vibration. Powerful waterproof bullet included. Truly the best among prostate massagers.
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
